Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.
Connective tissue diseases (CTDs) increase the risk for adverse maternal and fetal outcomes during pregnancy, with varying impacts across different CTD subtypes, according to study results published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback